VEGFA and retinitis pigmentosa 1: Given the role of vascular endothelial growth factor (VEGF) in neovascularization, treatment with anti-VEGF agents may be a viable option for managing the retinal neovascularization in patients with these complications [16]. Further research is warranted to investigate the prevalence, natural history, and underlying mechanisms of retinal neovascularization in RP, as well as to evaluate potential treatment strategies, including the use of anti-VEGF therapy.